December 2, 2020
Business News

Organigram Confirms Additional $2.5 Million Investment in Hyasynth Biologicals Inc. as Biosynthesis Pioneer Completes First Milestone Linked to First Sale of Commercial Product and Announces Executive Changes

MONCTON, New Brunswick–()–As an early investor in biosynthesis, Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), the parent company of Organigram Inc. (the “Company” or “Organigram”), a leading licensed producer of cannabis, is pleased to announce it has funded an additional $2.5 million investment in Hyasynth Biologicals Inc. (“Hyasynth”), a private biotechnology company and pioneer in the field of cannabinoid science and biosynthesis. The announcement comes as Hyasynth makes the first sale of CBDa1 produced and extracted from yeast.

In addition to the investment, Organigram continues to have the right to purchase potentially all of Hyasynth’s cannabinoid or cannabinoid related production at,…

Click here to view the original article.

Related Posts

You might also like ...

DeepCube Expands its Leadership Team with New Chief Executive Officer, Michael Zimmerman
Riassunto: Velodyne Lidar annuncia la collaborazione con Ford Otosan nel campo della guida autonoma
How Will the Recovery of Containerized Trade and the RCEP Trade Agreement Affect the Global Tank Container Shipping Market? Technavio